What have been Merck’s major milestones and achievements for its pharmaceutical division since you took the reins? I have been managing the…

Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in…

Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical markets. How have you observed this…

Mr. Bartoš, you are celebrating your 15th anniversary with Merck this year, and your international career has offered you the opportunity to…

Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks…

As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth…

What have been MSD’s major milestones and achievements since your establishment in Chile in 1995? We have recently gone through a global…

Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The…

You joined Merck in September 1996, took gradually increasing positions at Merck, from Medical Representative (1996 – 1998), to Sales and Marketing…

You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself…

You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the…